Setia Vishwas
Known title: Chief Financial OfficerCIK: 0002021256
Associated companies
Transaction History
| MPLT | ▼ Sell | Open Market | 8,496 | $238K | 5/6/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,068 | $60K | 5/6/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 9,935 | $279K | 5/5/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 968 | $28K | 5/5/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 4,803 | $131K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 8,989 | $254K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 325 | $10K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 787 | $24K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 29 | $783 | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 87 | $2K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,806 | $75K | 4/15/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 7,730 | $0 | 2/5/2026 | View on chart |
| MPLT | ▼ Sell | Tax Withholding | 33,382 | $600K | 1/27/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 43,367 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.